New CAR-T therapy trial opens for aggressive lymphomas that resist standard care
NCT ID NCT07382817
Summary
This is an early-stage study to test the safety and find the right dose of a new personalized cell therapy called JV-394. It is for adults with specific types of T or NK cell lymphomas that have come back or not responded to at least one prior treatment. The therapy involves collecting a patient's own immune cells, modifying them to target a protein called CD94 on the cancer, and then infusing them back.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Texas M. D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.